Lincoln Pharmaceuticals Limited (NSE:LINCOLN)

Market Cap	11.73B
Revenue (ttm)	6.23B
Net Income (ttm)	823.46M
Shares Out	n/a
EPS (ttm)	41.11
PE Ratio	14.24
Forward PE	n/a
Dividend	1.80 (0.31%)
Ex-Dividend Date	Sep 13, 2024

Volume	62,709
Average Volume	92,794
Open	582.50
Previous Close	585.95
Day's Range	567.95 - 590.45
52-Week Range	499.00 - 979.50
Beta	0.31
RSI	56.49
Earnings Date	May 20, 2025

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 1,687
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LINCOLN

Financial Performance

In 2024, Lincoln Pharmaceuticals's revenue was 6.23 billion, an increase of 7.35% compared to the previous year's 5.81 billion. Earnings were 823.46 million, a decrease of -11.74%.